NCT00185731View on ClinicalTrials.gov

Phase 2 Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
LeukemiaLymphoma, Non-Hodgkin
Interventions
DRUG

Atorvastatin

80 mg orally once daily

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
collaborator

The Leukemia and Lymphoma Society

OTHER

collaborator

Damon Runyon Cancer Research Foundation

OTHER

collaborator

Burroughs Wellcome

INDUSTRY

lead

Dean Felsher

OTHER

NCT00185731 - Phase 2 Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter